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ABSTRACT
Objectives: Early testing for HIV and entry into care
are crucial to optimise treatment outcomes of
HIV-infected patients and to prevent spread of HIV.
We examined risk factors for presentation with late or
advanced disease in HIV-infected patients in the
Netherlands.
Methods: HIV-infected patients registered in care
between January 1996 and June 2014 were selected
from the ATHENA national observational HIV cohort.
Risk factors for late presentation and advanced disease
were analysed by multivariable logistic regression.
Furthermore, geographical differences and time trends
were examined.
Results: Of 20 965 patients, 53% presented with late-
stage HIV infection, and 35% had advanced disease.
Late presentation decreased from 62% (1996) to 42%
(2013), while advanced disease decreased from 46%
to 26%. Late presentation only declined significantly
among men having sex with men (MSM; p <0.001),
but not among heterosexual males (p=0.08) and
females (p=0.73). Factors associated with late
presentation were: heterosexual male (adjusted OR
(aOR), 1.59; 95% CI 1.44 to 1.75 vs MSM), injecting
drug use (2.00; CI 1.69 to 2.38), age ≥50 years (1.46;
CI 1.33 to 1.60 vs 30–49 years), region of origin
(South-East Asia 2.14; 1.80 to 2.54, sub-Saharan
Africa 2.11; 1.88 to 2.36, Surinam 1.59; 1.37 to 1.84,
Caribbean 1.31; 1.13 to 1.53, Latin America 1.23; 1.04
to 1.46 vs the Netherlands), and location of HIV
diagnosis (hospital 3.27; 2.94 to 3.63, general
practitioner 1.66; 1.50 to 1.83, antenatal screening
1.76; 1.38 to 2.34 vs sexually transmitted infection
clinic). No association was found for socioeconomic
status or level of urbanisation. Compared with
Amsterdam, 2 regions had higher adjusted odds and 2
regions had lower odds of late presentation. Results
were highly similar for advanced disease.
Conclusions: Although the overall rate of late
presentation is declining in the Netherlands, targeted
programmes to reduce late HIV diagnoses remain
needed for all risk groups, but should be prioritised for
heterosexual males, migrant populations, people aged
≥50 years and certain regions in the Netherlands.
INTRODUCTION
The main public health goal of prevention
of HIV infection is to interrupt transmission
and to improve treatment outcomes for indi-
vidual HIV-infected patients. In the
Netherlands, primary and secondary HIV
prevention includes promotion of condom
use, screening programmes for pregnant
women and blood donors, routine testing of
high-risk populations, early referral into care,
and partner notiﬁcation.1–3
To optimise treatment outcomes for indi-
vidual patients, HIV should be as early as
possible but not later than at CD4 cell counts
below 350/mm3.4 Starting combination anti-
retroviral therapy (cART) at lower CD4
counts negatively affects prognosis as well as
HIV transmission and healthcare costs.5–7
The US Department of Health and Human
Services (DHHS) HIV treatment guidelines,8
which are adopted in the Netherlands,9
strongly recommend initiation of cART at
CD4 counts of 350–500/mm3 based on clin-
ical evidence, but based on expert opinion
cART should also be considered for every
patient with CD4 counts >500/mm3. And as
it recently became apparent that starting
cART in the early or even acute phase of
Strengths and limitations of this study
▪ Nationwide, longitudinal cohort enabling data
analysis over a 17-year period.
▪ Risk factors for presentation with late or
advanced HIV disease.
▪ Late presentation declined significantly among
men having sex with men, but not among het-
erosexual males and females.
▪ Co-infections with sexually transmitted infections
were either not collected or incomplete and were
excluded from the analysis.
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infection improves clinical prognosis, more countries are
expected to shift towards early recognition of symptoms
of acute infection, early linkage into care and immediate
treatment.8 10
In 2012, an estimated 24 350 (20 420–31 280) people
were living with HIV/AIDS in the Netherlands of whom
34% were either not diagnosed or diagnosed but not in
care.11 Of those diagnosed and in care, 54% was diag-
nosed late (CD4 counts <350/mm3).12 A study among
HIV patients in Rotterdam identiﬁed heterosexual trans-
mission, age of 50 years and older, and being of
sub-Saharan African or Asian origin as factors associated
with late diagnosis.13 The authors showed that more
than 75% of the patients before their late diagnosis
already experienced clinical symptoms described as HIV
indicator diseases (as published by ‘HIV in Europe’, an
expert group that promotes early diagnosis and earlier
care of HIV infections in Europe).14
In the present study, we examined the state of late
presentation (CD4<350/mm3, or AIDS-deﬁning event
regardless of CD4 count) and advanced HIV disease
(CD4<200/mm3, or AIDS-deﬁning event regardless of
CD4 count) for all patients registered between 1996 and
2014 in the Netherlands. We also studied whether late
presentation or advanced disease were related to speciﬁc
demographic or socioeconomic variables.
METHODS
We analysed data from ‘Stichting HIV Monitoring’ (SHM,
HIV Monitoring Foundation) from HIV-infected patients
registered between January 1996 and June 2014 in 27
HIV treatment centres in the Netherlands (the ATHENA
national observational HIV cohort).12 Sociodemographic
data (gender, age, region of origin, municipality, degree
of urbanisation, socioeconomic status (SES), location of
HIV diagnosis, HIV transmission route), and clinical data
(CD4 cell counts at diagnosis or ﬁrst entry into care, year
of HIV diagnosis, CDC event at diagnosis) were included
in the analyses. CDC events were classiﬁed according to
the classiﬁcation of the US Centers for Disease Control
and Prevention.15 CD4 count at time of diagnosis was
deﬁned as the ﬁrst CD4 count within 3 months after diag-
nosis. HIV-infected patients were classiﬁed according to a
consensus deﬁnition as presented by the European Late
Presenter Consensus working group,16 which deﬁned late
presentation if a patient is diagnosed with a CD4+ T-cell
count <350/mm3 or if a patient presents with a CDC-C
event (AIDS-deﬁning illness) regardless of CD4 count.
Advanced HIV disease was deﬁned as a diagnosis with a
CD4+ T-cell count <200/mm3, or with a CDC-C event
regardless of CD4 count. Baseline characteristics of these
groups were compared with patients presenting ‘timely
or non-late’ (CD4+ T-cell count >500/mm3 and no
AIDS-deﬁning illness).
Ethnic groups were categorised to reﬂect the main
group of immigrants in the Netherlands, based on
country of birth of the patient. The location where
patients were tested and diagnosed with HIV was avail-
able from 2008 onwards. In case location of diagnosis
was missing, location of referral was used. A ‘status
score’ computed by the Netherlands Institute for Social
Research (SCP, available at: http://www.scp.nl) was used
as a proxy for SES. This score takes into account the
average income per household in a given postal code
area as well as the percentage of households with low
income, without paid job, and with low education level.
Scores varied between −3.40 and +5.20 and were divided
in ﬁve classes: very wealthy (lowest to −1.50), wealthy
(−1.50 to −0.50), average (−0.50 to +0.50), less favoured
(+0.50 to +1.50) and deprived (+1.50 to highest). Level
of urbanisation was divided in ﬁve classes based on the
average neighbourhood address density (NAD): highly
urbanised (NAD>2500 or more addresses/km2), urba-
nised (NAD 1500–2500 addresses/km2), moderate
urban (NAD 1000–1500 addresses/km2), less urbanised
(NAD 500–1000 addresses/km2), rural (NAD <500
addresses/km2). Patients were divided into 27 public
health regions (areas covered by public health services)
based on postal codes of the residence of the patients at
the time of diagnosis (available from 2003 onwards), for
Geographical Information System (GIS) analysis using
the ArcGIS 9.3 software program. Choosing public
health regions as level of analysis is more detailed than
using provinces (n=12) and could potentially identify
variation due to differences in prevention activities of
the public health services.
Trends over time in late presentation and advanced
disease for different transmission groups were analysed
with the Cochran Armitage trend test for categorical vari-
ables. Risk factors for late presentation and advanced
disease were analysed by univariable and multivariable
logistic regression using the SAS V.9.3 statistical software
program. Variables that showed an association of p<0.20
(Wald test, univariable analysis) were included in the
multivariable analyses. Multivariable analyses with back-
ward selection included variables with p<0.05 for the like-
lihood ratio test. As the current treatment guidelines
strongly recommend cART for all individuals with CD4+
T-cell count <500/mm3 based on clinical evidence,8 9 the
multivariable analysis was repeated for a larger group of
patients, those with ‘delayed presentation’ (deﬁned as
having a CD4 count of <500/mm3 or AIDS-deﬁning
event regardless of CD4 count) to examine if additional
risk factors could be identiﬁed. Although the clinical rele-
vance to identify patients with CD4 counts of 350–500/
mm3 is smaller compared with patients with lower CD4
counts, identifying patients with CD4 <500/mm3 remains
important from the public health perspective to prevent
further transmission of HIV.17
RESULTS
Patient characteristics
In total, 22 311 HIV-infected patients were registered
into care in the Netherlands between 1996 and 2014.
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Patients with HIV-2 (n=97), HIV-2/HIV-1 co-infections
(n=61), and children under the age of 14 (n=550) were
excluded from the analyses as patterns of CD4 counts at
diagnosis might be different. For 20 965 (97%) of the
21 603 remaining patients, information regarding
AIDS-deﬁning illnesses and CD4 count at diagnosis or at
ﬁrst entry into care at the HIV clinic was available and
were included in the analyses. The majority of these
patients were men who have sex with men (MSM; 59%),
of Dutch origin (57%), and living in an area with
highest population density (53%; table 1).
Overall, 73% were ‘delayed’ presenters, 53% pre-
sented late and 35% had advanced HIV disease at
diagnosis or entry into care. ‘Timely’ presenters (27%)
had a median CD4 count of 640 cells/mm3 (IQR 544–
783) at diagnosis compared with 150 cells/mm3 (50–
270) for late presenters and 80 (30–155) for patients
with advanced disease (table 1). Of the 7331 patients
who presented with advanced disease, 26% had AIDS
at time of diagnosis. Patients presenting late or with
advanced disease were more often diagnosed in a hos-
pital, while patients presenting timely were more often
diagnosed at an sexually transmitted infection (STI)
clinic.
Percentages of late presentation by main transmission
group and region of origin are shown for recent years in
ﬁgure 1. MSM overall showed the lowest percentages of
late presentation, but still varying from 31% for
Surinamese MSM to 54% for South-East Asian MSM.
Highest percentages of late presentation were found
among heterosexuals from South-East Asia (women:
79%, men: 73%), sub-Saharan Africa (women: 63%,
men: 73%) and Surinam (women: 64%, men: 69%). A
large difference was observed between Dutch heterosex-
ual men and women, with 60% of men and 36% of
women presenting late.
Trends
Median CD4 counts at time of HIV diagnosis of the total
study population increased signiﬁcantly from 240 cells/
mm3 in 1996 to 410 cells/mm3 in 2013 (p<0.001). The
overall percentages of patients entering care late or with
advanced disease declined signiﬁcantly between 1996
and 2013 (p<0.001); from 62% to 42% among late pre-
senters and from 46% to 26% in patients with advanced
disease. Trend analysis of late presentation by main
transmission group showed a signiﬁcant decline for
MSM, from 59% (n=274) in 1996 to 33% (n=205) in
2013 (p<0.001), but not for heterosexual males
(p=0.08) and females (p=0.73; ﬁgure 2) with 72 respect-
ively 57 cases in 2013. Stratiﬁcation by age groups at
time of diagnosis (<30, 30–49, >50 years) showed a sig-
niﬁcant decline of late presentation for each age group
among MSM (p<0.01), but for none of the age groups
among heterosexuals (data not shown). Trends were
very similar for advanced HIV disease and are therefore
not shown.
Factors associated with presenting late or with advanced
disease
Patients diagnosed in recent years (>2008) had lower
odds of late presentation (adjusted OR (aOR) 0.55; 95%
CI 0.51 to 0.59) compared with patients diagnosed
before 2008 (table 2).
Younger patients (<30 years of age) had lower odds of
late presentation compared with 30–39 year olds (aOR
0.63, CI 0.59 to 0.68), but being older than 50 years of
age was associated with increased odds of late presenta-
tion (aOR 1.46, CI 1.33 to 1.60).
Heterosexual men (aOR 1.59, CI 1.44 to 1.75) and
injecting drug users (IDUs; OR 2.00, CI 1.69 to 2.38)
were more likely to present late compared with MSM,
but heterosexual women had similar odds (aOR 0.98, CI
0.89 to 1.08). Yet, it should be noted that although het-
erosexual males are more likely to present late com-
pared with MSM, in absolute numbers the majority of
late presenters in the Netherlands are MSM. Similarly
for age groups, although being aged >50 years was asso-
ciated with greater odds of presenting late, the median
age of late presenters was 37 (IQR 30–45), so half of the
late presenters were aged 37 or under.
In addition, patients originating from South-East Asia
(aOR 2.14, CI 1.80 to 2.54), sub-Saharan Africa (aOR
2.11, CI 1.88–2.36), Surinam (aOR 1.59, CI 1.37 to
1.84), the Caribbean (aOR 1.31, CI 1.13 to 1.53) or
Latin America (aOR 1.23, CI 1.04 to 1.46) were more
likely to present late compared with patients of Dutch
origin. Late presentation was also more common in
patients who were diagnosed with HIV in a hospital
(aOR 3.27, CI 2.94 to 3.63), a general practitioner (GP;
aOR 1.66, CI 1.50 to 1.83) or through antenatal screen-
ing (aOR 1.76, CI 1.38 to 2.24). SES and population
density were not associated with late diagnosis. Stratiﬁed
models for MSM and heterosexuals showed similar risk
factors for late presentation, which was also illustrated by
non-signiﬁcant interaction terms for transmission cat-
egory with other variables in the overall model including
all transmission groups.
The models for advanced disease (table 2) and
‘delayed’ presentation (not shown) showed the same
risk factors with highly similar aORs. However, in the last
model, a small association for population density was
observed: patients living in an average-urbanised or
less-urbanised area had slightly higher odds of present-
ing ‘delayed’ (aOR 1.17, CI 1.02 to 1.34 and aOR 1.19,
CI 1.03 to 1.38, respectively) compared with patients
living in a highly urbanised area.
Regional differences
Geostatistics using GIS software was used to provide
insight in regional variability in proportions of late diag-
noses for the 27 public health regions in the
Netherlands in recent years, for the total population
(ﬁgure 3A) and for MSM separately (ﬁgure 3B). Public
health regions with overall proportions of late presenta-
tion higher than 50% tended to be more located in the
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Table 1 Characteristics of HIV patients with non-late presentation, late presentation and advanced disease in the
Netherlands, January 1996 to June 2014
HIV patients in care, total
(n=20 965, 100%)
N (%)
‘Timely’ presentation
(n=5756, 27%)
N (%)
Late presentation
(n=11 182, 53%)
N (%)
Advanced disease
(n=7331, 35%)
N (%)
Year of diagnosis
<2001 7762 (37) 1631 (28) 4803 (43) 3373 (46)
2002–2007 6603 (32) 1915 (33) 3441 (31) 2205 (30)
2008> 6600 (31) 2210 (38) 2938 (26) 1743 (24)
Gender
Male 16 877 (80) 4717 (82) 8851 (79) 5829 (80)
Female 4088 (20) 1039 (18) 2331 (21) 1502 (20)
Transmission category
MSM 12 314 (59) 3909 (68) 5717 (51) 3535 (48)
Heterosexual, male 2940 (14) 525 (9) 1984 (18) 1425 (19)
Heterosexual,
female
3636 (17) 945 (16) 2043 (18) 1300 (18)
IDU 701 (3) 128 (2) 475 (4) 336 (5)
Other/unknown 1374 (7) 249 (4) 1056 (9) 735 (10)
Median age (IQR) 36 (29–44) 35 (28–43) 37 (30–45) 38 (31–46)
Municipality
Amsterdam 6283 (30) 1815 (32) 3198 (29) 2027 (28)
Other 14 682 (70) 3941 (68) 7984 (71) 5304 (72)
Region of origin
The Netherlands 11 913 (57) 3643 (63) 5866 (52) 3808 (52)
Europe, else 2006 (10) 626 (11) 962 (9) 627 (9)
SSA 3201 (15) 544 (9) 2156 (19) 1424 (19)
Surinam 928 (4) 215 (4) 568 (5) 377 (5)
Netherlands
Antilles/Caribbean
821 (4) 221 (4) 443 (4) 291 (4)
Latin America 621 (3) 172 (3) 306 (3) 192 (3)
South-East Asia 712 (3) 132 (2) 470 (4) 337 (5)
Else/unknown 763 (4) 203 (4) 411 (4) 275 (4)
Probable country of infection (n=15 363)
The Netherlands 11 285 (54) 3536 (61) 5419 (48) 3438 (47)
Abroad 4078 (19) 997 (17) 2395 (21) 1562 (21)
Population density (n=20 074)
Highly urbanised 11 168 (53) 3209 (56) 5749 (51) 3683 (50)
Urbanised 4298 (20) 1215 (21) 2294 (21) 1502 (20)
Moderate urban 1901 (9) 484 (8) 1044 (9) 686 (9)
Less urbanised 1496 (7) 391 (7) 785 (7) 505 (7)
Rural 1211 (6) 343 (6) 630 (6) 421 (6)
SES (n=20 028)
Very wealthy 1015 (5) 297 (5) 525 (5) 319 (4)
Wealthy 4396 (21) 1278 (22) 2214 (20) 1391 (19)
Average 5638 (27) 1595 (28) 2919 (26) 1930 (26)
Less favoured 5125 (24) 1454 (25) 2675 (24) 1771 (24)
Deprived 3854 (18) 1008 (18) 2144 (19) 1373 (19)
Location of HIV diagnosis (n=14 938)
STI clinic 2782 (13) 1217 (21) 845 (8) 322 (4)
General practitioner 6468 (31) 1967 (34) 3081 (28) 1777 (24)
Hospital 5342 (25) 1008 (17) 3592 (32) 2797 (38)
Antenatal
screening
346 (2) 103 (2) 175 (2) 85 (1)
Else/unknown 6027 (29) 1461 (25) 3489 (31) 2350 (32)
Median CD4 count
(cells/mms, IQR)
336 (140–540) 640 (544–783) 150 (50–270) 80 (30–155)
Vertical transmission and children under the age of 14 excluded; late presentation: CD4<350 cells/mm3 or AIDS-defining event regardless of
CD4 count; advanced disease: CD4<200 cells/mm3 or AIDS-defining event regardless of CD4 count, non-late presentation: CD4>500 cells/
mm3 and no AIDS-defining event.
IDU, injecting drug user; MSM, men having sex with men; SES, socioeconomic status; SSA, sub-Saharan Africa; STI, sexually transmitted
infection.
4 Op de Coul ELM, et al. BMJ Open 2016;6:e009688. doi:10.1136/bmjopen-2015-009688
Open Access
group.bmj.com on May 30, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Eastern part of the country: ‘Rivierenland’, ‘Drenthe’,
‘Gelderland’ and ‘Limburg-Noord’. For the ﬁrst two
regions, proportions of late presentation were also high
for MSM. Seven regions, mostly in the West (including
Amsterdam) or South of the Netherlands, showed pro-
portions of late presentation of 40% or lower.
With multivariable logistic regression, adjusting for
other covariates, we examined whether regional differ-
ences could be explained by other factors, such as differ-
ent distributions of transmission groups or ethnic
groups, or whether differences were associated with
(unidentiﬁed factors in) the region itself (table 2). The
model was repeated for a recent period (2010–2014) to
improve comparison with the geographic map; however,
results were similar to the overall model using the com-
plete database, but CIs were wider and the model ﬁt was
weaker (Hosmer and Lemeshow goodness of ﬁt p<0.01).
In multivariate model, only two regions had signiﬁcantly
higher odds of late presentation compared with
Amsterdam (used as reference category due to larger
number of patients): ‘Rotterdam-Rijnmond’ (aOR 1.12,
CI 1.01 to 1.25, overall model) and ‘Groningen’ (aOR
1.23, CI 1.01 to 1.51, overall model, but also signiﬁcant
in the 2010–2014 model). Of these two regions,
‘Groningen’ showed the highest proportion of late diag-
noses in the geographic map: 48%.
Two Southern regions ‘Brabant-Zuidoost’ (aOR 0.68,
CI 0.78 to 0.82) and ‘West-Brabant’ (aOR 0.78, CI 0.63
to 0.97) had signiﬁcantly lower odds of late presentation
compared with Amsterdam (table 2) of which ‘Brabant
Zuidoost’ was signiﬁcant in both models. The propor-
tion of late diagnoses in that region was 33% compared
with 40% in Amsterdam.
DISCUSSION
Of the 20 965 HIV patients registered into care between
1996 and 2014 in the Netherlands, 73% presented
‘delayed’, 53% presented late and 35% had advanced
HIV disease. Percentages of presenting late in the
course of HIV infection were particularly high among
heterosexual males, IDU, patients from sub-Saharan
Figure 1 Percentages of late presentation (CD4<350 cells/mm3 or AIDS-defining event regardless of CD4 count) for 2010–
2014, by transmission group (men having sex with men (MSM), heterosexual male, female) and region of origin.
Figure 2 Percentages of late presentation (CD4<350 cells/mm3 or AIDS-defining event regardless of CD4 count), by year of
diagnosis and transmission group (MSM, men having sex with men).
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Africa, South-East Asia or Surinam, patients age 50 and
older, and patients diagnosed in hospitals. In addition,
certain regions in the Netherlands were associated with
a higher risk for late presentation. Risk factors associated
with advanced disease were highly similar in this study
population, but groups are also overlapping.
One of the strengths of our study is the large number
of patients included from a non-selective nationwide,
longitudinal cohort, which made it possible to study
regional differences as well as time trends over a 17-year
period. Also, the quality of the data is high: for 97% of
the eligible patients CD4 counts at diagnosis or ﬁrst
entry into care and information on AIDS-deﬁning ill-
nesses was available. However, data were less complete
for probable country of infection (73%) and location of
HIV diagnosis (71%). Furthermore, variables shown to
be associated with late presentation in other settings,18–
23 such as education level or co-infections with STIs,
were either not collected or incomplete and could
therefore not be included in our analysis.
Table 2 Risk factors for late presentation and advanced disease for HIV patients in the Netherlands, registered between
January 1996 and June 2014
Late presentation
Univariable OR
(95% CI)
Late presentation
Multivariable aOR
(95% CI)
Advanced disease
Univariable OR
(95% CI)
Advanced disease
Multivariable aOR
(95% CI)
Period of diagnosis
<2001 1 1 1 1
2002–2007 0.67 (0.63 to 0.72) 0.63 (0.59 to 0.68) 0.65 (0.61 to 0.70) 0.62 (0.58 to 0.67)
2008> 0.49 (0.46 to 0.53) 0.55 (0.51 to 0.59) 0.46 (0.43 to 0.50) 0.51 (0.47 to 0.55)
Age (years)
<30 0.70 (0.65 to 0.74) 0.63 (0.59 to 0.68) 0.64 (0.60 to 0.68) 0.59 (0.55 to 0.64)
30–49 1 1 1 1
>50 1.32 (1.22 to 1.44) 1.46 (1.33 to 1.60) 1.36 (1.25 to 1.48) 1.46 (1.33 to 1.60)
Transmission category
MSM 1 1 1 1
Heterosexual, male 2.40 (2.20 to 2.61) 1.59 (1.44 to 1.75) 2.34 (2.15 to 2.54) 1.62 (1.47 to 1.79)
Heterosexual, female 1.48 (1.37 to 1.59) 0.98 (0.89 to 1.08) 1.38 (1.28 to 1.49) 1.03 (0.93 to 1.14)
IDU 2.42 (2.06 to 2.85) 2.00 (1.69 to 2.38) 2.29 (1.96 to 2.67) 1.85 (1.57 to 2.18)
Other/unknown 2.70 (2.39 to 3.05) 1.73 (1.52 to 1.97) 2.85 (2.55 to 3.20) 1.88 (1.66 to 2.13)
Region of origin
The Netherlands 1 1 1 1
Europe, else 0.95 (0.86 to 1.04) 1.13 (0.96 to 1.32) 0.97 (0.87 to 1.07) 0.94 (0.83 to 1.05)
SSA 2.13 (1.96 to 2.31) 2.11 (1.88 to 2.36) 1.71 (1.58 to 1.85) 1.64 (1.46 to 1.84)
Surinam 1.63 (1.42 to 1.87) 1.59 (1.37 to 1.84) 1.46 (1.27 to 1.67) 1.37 (1.18 to 1.60)
Netherlands Antilles/Caribbean 1.21 (1.05 to 1.39) 1.31 (1.13 to 1.53) 1.17 (1.01 to 1.36) 1.27 (1.08 to 1.50)
Latin America 1.00 (0.85 to 1.18) 1.23 (1.04 to 1.46) 0.95 (0.80 to 1.13) 1.23 (1.02 to 1.49)
South-East Asia 2.00 (1.71 to 2.35) 2.14 (1.80 to 2.54) 1.91 (1.64 to 2.23) 2.07 (1.75 to 2.45)
Else/unknown 1.20 (1.04 to 1.40) 1.13 (0.96 to 1.32) 1.20 (1.03 to 1.40) 0.99 (0.90 to 1.09)
Residence (PH region)
Amsterdam 1 1 1 1
Brabant Zuidoost 0.73 (0.62 to 0.87) 0.68 (0.78 to 0.82) 0.77 (0.64 to 0.94) 0.70 (0.57 to 0.86)
West-Brabant 0.78 (0.65 to 0.95) 0.78 (0.63 to 0.97) 0.85 (0.69 to 1.05) 0.85 (0.67 to 1.06)
The Hague 1.05 (0.93 to 1.18) 0.89 (0.78 to 1.02) 1.00 (0.88 to 1.14) 0.83 (0.72 to 0.96)
Groningen 1.28 (1.07 to 1.54) 1.23 (1.01 to 1.51) 1.39 (1.16 to 1.67) 1.30 (1.06 to 1.60)
Rotterdam-Rijnmond 1.22 (1.10 to 1.34) 1.12 (1.01 to 1.25) 1.27 (1.15 to 1.40) 1.16 (1.04 to 1.29)
Location of referral
STI clinic 1 1 1 1
General practitioner 2.09 (1.90 to 2.29) 1.66 (1.50 to 1.83) 2.89 (2.54 to 3.29) 2.27 (1.99 to 2.60)
Hospital 4.70 (4.26 to 5.19) 3.27 (2.94 to 3.63) 8.40 (7.39 to 9.54) 5.87 (5.14 to 6.71)
Antenatal screening 2.34 (1.87 to 2.94) 1.76 (1.38 to 2.24) 2.49 (1.90 to 3.26) 2.09 (1.57 to 2.78)
Else/unknown 3.15 (2.86 to 3.47) 1.93 (1.73 to 2.15) 4.88 (4.30 to 5.54) 2.95 (2.57 to 3.38)
Vertical transmission and children under the age of 14 excluded from the models; late presentation: CD4<350/mm3 or AIDS-defining event
regardless of CD4 count; advanced disease: CD4<200/mm3 or AIDS-defining event regardless of CD4 count. Factors that were not significant
in the multivariable models for late presentation and advanced HIV disease were not shown (probable country of infection, SES, population
density). Municipality was only shown for categories that were significant. Interaction terms were NS. Bold values indicate significant values.
Missing values included in the model. ‘Public health region’ was significantly associated but not shown in the table due to large number of
categories (n=27).
aOR, adjusted OR; IDU, injecting drug user; MSM, men having sex with men; NS, non-significant; SES, Socioeconomic status; SSA,
sub-Saharan Africa.
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As the importance of early cART initiation for clinical
prognosis became more evident10 and current treatment
guidelines recommend the initiation of cART regardless
of CD4 counts,8 9 the overall proportions between 35%
for advanced disease and 73% for ‘delayed’ presentation
are very high. However, other European studies found
comparable high proportions of patients presenting
late,18–23 and risk factors of late presentation were very
similar to those found in our study. In most studies, the
likelihood of late presentation was lower for MSM com-
pared with other risk groups. Although the overall pro-
portion of late presenters declined over time in the
Netherlands, this is mainly due to earlier diagnosis of
HIV among MSM, but not among other risk groups. The
decline in late presentation among MSM is likely the
result of intensiﬁed HIV testing strategies, such as
opt-out HIV testing at STI clinics and the encourage-
ment of high-risk MSM to test for HIV every 6 months.24
In addition, internet facilities for HIV testing and
partner notiﬁcation were established25 26 that may have
resulted in earlier diagnoses among MSM.3 For hetero-
sexuals, especially men and migrant populations, effect-
ive HIV testing strategies have been lacking and a more
proactive offer of HIV testing in different healthcare set-
tings is urgently needed to reduce the unacceptably
high rates of late diagnoses. For example, HIV screening
among patients with tuberculosis (TB) should be
improved, as for only 51% of all patients with TB in the
Netherlands in 2013 the HIV status was registered,27
while the Dutch TB guideline recommends HIV screen-
ing for all patients with TB. Furthermore, asylum seekers
and refugees are only routinely screened for TB,
whereas guidelines in the USA and Canada recommend
that all asylum seekers and refugees from HIV-endemic
countries should be screened for TB, HIV and hepatitis
B.28 29 The high HIV prevalence among pregnant
asylum seekers from sub-Saharan Africa underlines the
importance of offering all newly arriving asylum seekers
from high prevalence areas a voluntary HIV test.30
Women in the Netherlands may have beneﬁted from
antenatal screening, in which HIV is routinely tested,31
since the odds of late presentation for women were com-
parable to MSM.
As one-third of all HIV infections in the Netherlands
are diagnosed by GPs,1 GPs could play an important role
in earlier detection of HIV in speciﬁc risk groups.
However, GPs tend to have a restrictive policy in offering
HIV tests,6 32 in particular in areas with a low reported
HIV prevalence. Recently, the GP guideline for STI/HIV
testing33 was adjusted to an indicator condition-guided
testing strategy14 34 including targeted testing of high-
risk populations such as people from HIV-endemic
areas. Besides ethnic background of patients, we were
not able to identify clear associations for socioeconomic
Figure 3 (A) Percentages of late presentation (CD4<350 cells/mm3 or AIDS-defining event regardless of CD4 count) in 2010–
2014 in the Netherlands, by public health region (overall population). (B) Percentages of late presentation (CD4<350 cells/mm3 or
AIDS-defining event regardless of CD4 count) in 2010–2014 in the Netherlands, by public health region (men having sex with
men (MSM) only).
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factors with late presentation such as low education (not
collected), and low SES (not signiﬁcant).18–23 35 36 Only
a small association with ‘delayed’ presentation was
observed for living in less-urbanised areas. In those areas
or in areas with low HIV prevalence, the risk for late
diagnosis might be higher as GPs may not recognise
HIV infections in their practice and people in those
areas may be less aware of risks of HIV transmission.
This highlights the need to start indicator condition-
guided HIV testing in GP practices across the
Netherlands. Furthermore, an additional testing strategy
could help to reduce the number of undiagnosed HIV
patients and patients with more advanced disease, that
is, if GPs would offer opt-out HIV testing in all practices
located in high prevalence areas (>2 infections/1000
inhabitants) to their newly registered patients or anyone
receiving a blood test.37 38
Patients diagnosed in hospitals had the highest odds
of presenting late or with advanced disease, which likely
illustrates patients who appear with aids-deﬁning events
in a hospital and were then tested for HIV. However,
HIV indicator condition-guided testing should also be
implemented in all hospitals if not already done.
Furthermore, direct referral to an HIV treatment centre
after diagnosis is needed as a Dutch study showed that
31% of newly diagnosed patients entered HIV care with
a delay of >4 weeks,39 and 16% were not registered in
care at the end of follow-up (>2 years). Patients who
were younger (<25 years of age), with non-Western eth-
nicity or no health insurance were more likely to enter
care late after HIV diagnosis as well as those being
referred indirectly. The authors concluded that testing
those at risk is not sufﬁcient in the Netherlands, but
timely entry into care needs to be assured as well. For
patients of 50 years and older, early detection and refer-
ral has additional importance since these patients tend
to have higher mortality rates in the ﬁrst years of treat-
ment.40 In general, older people may perceive them-
selves at lower risk than younger people, but also
healthcare providers may consider HIV testing less often
in older patients.
In conclusion, our results can be used to contribute to
current efforts to improve HIV testing practices in the
Netherlands to prevent late HIV diagnoses and reduce
the proportions of undiagnosed. Subsequently, this may
result in improved treatment outcomes,10 41 and less
ongoing transmission. In a country where cART is widely
available and highly accessible, the high proportions of
late presenters are staggering and need to decline. This
can only happen if populations at risk are aware of their
risks and have themselves tested for HIV, and if indicator
condition-guided HIV testing becomes part of routine
care in various settings. Targeted programmes to reduce
late HIV diagnoses are therefore needed for all risk
groups in the Netherlands, but heterosexual males,
migrant populations, people older than 50 years of age,
and certain regions need special priority.
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